美国FDA药品溶出方法数据库

药品通用名称	剂型	USP溶出装置	速度	溶出介质	介质体积	建议取样时间（分钟）	更新日期
Elacestrant Dihydrochloride	Tablet	II (Paddle)	75	0.01 N HCl	500 for 100 mg; 1000 for 400 mg	5, 10, 15, 30, 45 and 60	2024/05/31
Elafibranor	Tablet	II (Paddle)	50	0.1% sodium dodecyl sulfate (SDS) in phosphate buffer, pH 6.8	900	10, 15, 20, 30, 45 and 60	2026/01/28
Elagolix Sodium	Tablet	II (Paddle)	50	0.05 M Sodium Phosphate, pH 6.8	900	5, 10, 15, 20, 30 and 45	2021/04/22
Elagolix Sodium, Estradiol, Norethindrone Acetate; Elagolix Sodium	Capsule	Elagolix: I (Basket)	Elagolix: 100	Elagolix: 0.05M Sodium Phosphate pH 6.8		10, 15, 20, 25, 30, 45, 60 and 90	2024/02/05
Elbasvir/Grazoprevir	Tablet	I (Basket)	100	Phosphate Buffer, pH 6.8 with 0.45% (w/v) Polysorbate 80	900	10, 15, 20, 30, 45 and 60	2016/07/28
Eletriptan Hydrobromide	Tablet	I (Basket)	100	0.1 N HCl	900	5, 10, 15 and 30	2009/04/02
Elexacaftor (Ele); Ivacaftor (Iva); Tezacaftor (Tez)	GRANULES	II (Paddle)	65	Ele: 1.8% (v/v) Tween 20 in 50 mM sodium phosphate, pH 6.8 Tez: 0.1% (w/v) SLS in 0.1 N HCl Iva: 0.4% (w/v) SLS in 50 mM sodium phosphate buffer, pH 6.8	900	5, 10, 15, 20, 30, 45, 60 and 75	2026/01/28
Elexacaftor, Ivacaftor, Tezacaftor [FDC:ELE+ IVA+ TEZ]; Ivacaftor [IVA]	Tablet/Tablet (Copackage)	II (Paddle)	FDC: ELE: 75/IVA: 65/TEZ:75; IVA: 75	FDA: ELE: 1.8% (v/v) Polysorbate 20 in 50 mM sodium phosphate, pH 6.8/ IVA: 0.4% (w/v) SLS in 50 mM sodium phosphate, pH 6.8/TEZ: 0.2% (w/v) SLS solution in 0.1N HCl; IVA: 1.8% (v/v) Polysorbate 20 in 50 mM sodium phosphate, pH 6.8	FDC: ELE: 900/IVA: 900/TEZ:900; IVA 900	5, 10, 15, 20 and 30	2021/08/19
Eliglustat Tartrate	Capsule			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Eltrombopag Choline	Tablet	II (Paddle)	75	0.25% Tween 80 in 0.05 M pH 6.8 Potassium Phosphate Buffer, pH 6.8	900	5, 10, 15, 20, 30, 45 and 60	2026/01/28
Eltrombopag Olamine	Tablet	II (Paddle)	50	0.5% Polysorbate 80 in Phosphate Buffer, pH 6.8	900	10, 15, 20, 30, 45, and 60	2012/06/07
Eltrombopag Olamine	Suspension	II (Paddle)	50	50 mM potassium phosphate in water, pH 6.8 with 0.2% polysorbate 80	750	4, 8, 12, 15 and 20	2016/10/20
Eluxadoline	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Elvitegravir	Tablet	II (Paddle) with sinker	75	2.0% w/v Polysorbate 80 in 0.01 N HCl (pH 2.0) at 37 ºC	700 mL for 85 mg tablets; 1000 mL for 150 mg tablets 1000 mL for 150 mg tablets	10, 20, 30, 45 and 60	2015/12/24
Empagliflozin	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Empagliflozin/ Metformin HCl	Tablet (Extended Release)	I (Basket)	100	Phosphate Buffer, pH 6.8	900	Metformin: 1, 2, 4, 6, 8, 10 and 12 hours: Empagliflozin: 10, 15, 20, 30, 45 and 60 minutes;	2017/01/19
Empagliflozin/Linagliptin	Tablet	II (Paddle)	50	pH 6.8 Phosphate Buffer	900	10, 15, 20, 30 and 45	2015/12/24
Empagliflozin/Linagliptin/Metformin HCl	Tablet (Extended Release)	I (Basket)	100	Phosphate Buffer, pH 6.8	900	Metformin: 1, 2, 4, 6, 8, 10 and 12 hours: Empagliflozin and Linagliptin: 10, 15, 20, 30, 45 and 60 minutes	2020/04/02
Empagliflozin/Metformin HCl	Tablet	II (Paddle)	50	Phosphate Buffer, pH 6.8 (degas)	900	5, 10, 15, 20 and 30	2016/06/30
Emtricitabine	Capsule			Refer to FDA's Dissolution Guidance, 2018			2020/07/02